Zynex Enters Chapter 11 and Faces Nasdaq Delisting

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialThe latest announcement is out from Zynex ( (ZYXI) ). On December 15, 2025, Zynex, Inc. and certain subsidiaries filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas and entered into a restructuring support agreement with key noteholders and debtor-in-possession (DIP) lenders to back a $22.3 million senior secured DIP term loan. The DIP Facility, approved on an interim basis on December 17, 2025, provides three milestone-based draws, carries a 10% paid-in-kind interest rate plus multiple fees and a 2.0x minimum return on invested capital, matures the earlier of 105 days after the petition date, acceleration upon default, or a sale of substantially all assets, and is secured by a priming lien on virtually all of the company’s assets to fund Chapter 11 costs and ongoing working capital. Also on December 17, 2025, Nasdaq notified Zynex that it would delist the company’s common stock due to the Chapter 11 filings, with trading to be suspended on December 24, 2025 and a Form 25-NSE to be filed; Zynex does not plan to appeal and expects its shares may trade on an OTC Markets venue, while warning that trading in its securities during the bankruptcy is highly speculative and that equity holders are likely to incur significant losses under the contemplated restructuring. The most recent analyst rating on (ZYXI) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page. Spark’s Take on ZYXI Stock According to Spark, TipRanks’ AI Analyst, ZYXI is a Underperform. Zynex’s overall stock score is significantly impacted by its poor financial performance, with declining revenues, high leverage, and negative equity. The technical analysis further indicates a bearish trend, while the valuation is unattractive due to a negative P/E ratio. The earnings call and corporate events highlight ongoing financial and operational challenges, despite strategic initiatives. To see Spark’s full report on ZYXI stock, click here. More about Zynex Zynex, Inc. is a medical technology company that develops and markets electrotherapy and pain management devices, with a focus on patients requiring non-invasive therapeutic solutions, and its securities are listed on public markets, including the Nasdaq prior to the events described. Average Trading Volume: 5,007,434 Technical Sentiment Signal: Sell Current Market Cap: $10.34M For a thorough assessment of ZYXI stock, go to TipRanks’ Stock Analysis page.